Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test

Gómez-Camarero, P.; Tena, A. Ortiz-de; Borrego-Dorado, I.; Vázquez-Albertino, R.; Navarro-González, Elena; Ruiz-Franco-Baux, J.; Cuenca-Cuenca, J.I.

doi:10.1016/j.remnie.2012.07.012

Cited by 6 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-seven articles evaluating the role of FDG-PET or PET/CT in patients with recurrent MTC were selected and retrieved from the literature (Tables 1 and 2 ) [ 5 – 8 , 10 , 12 – 33 ]. Other six articles were not included for possible data overlap [ 34 – 39 ].…”

Section: Literature Datamentioning

confidence: 99%

PET Imaging in Recurrent Medullary Thyroid Carcinoma

Treglia

Rufini

Salvatori

et al. 2012

International Journal of Molecular Imaging

View full text Add to dashboard Cite

Purpose. To perform an overview about the role of positron emission tomography (PET) or PET/computed tomography (PET/CT) using different radiopharmaceuticals in recurrent medullary thyroid carcinoma (MTC) based on biochemical findings (increased tumor marker levels after primary surgery). Methods. A comprehensive literature search of studies published in PubMed/MEDLINE, Scopus, and Embase databases through February 2012 regarding PET or PET/CT in patients with recurrent MTC was performed. Results. Twenty-nine studies comprising 714 patients with suspected recurrent MTC were retrieved. Twenty-seven articles evaluated the role of fluorine-18-fluorodeoxyglucose (FDG) PET or PET/CT in recurrent MTC with conflicting results. Diagnostic accuracy of FDG-PET and PET/CT increased in MTC patients with higher calcitonin and carcinoembryonic antigen values, suggesting that these imaging methods could be very useful in patients with more advanced and aggressive disease. Eight articles evaluated the role of fluorine-18-dihydroxyphenylalanine (FDOPA) PET or PET/CT in recurrent MTC reporting promising results. Overall, FDOPA seems to be superior but complementary compared to FDG in detecting recurrent MTC. Few studies evaluating other PET tracers are also discussed. Conclusions. PET radiopharmaceuticals reflect different metabolic pathways in MTC. FDOPA seems to be the most useful PET tracer in detecting recurrent MTC based on rising levels of tumor markers. FDG may complement FDOPA in patients with more aggressive MTC.

show abstract

Section: Literature Datamentioning

confidence: 99%

PET Imaging in Recurrent Medullary Thyroid Carcinoma

Treglia

Rufini

Salvatori

et al. 2012

International Journal of Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…According to a metaanalysis of 15 studies, the pooled sensitivities of 18 F-FDG-PET and PET/CT were 68 and 69 %, respectively [10]. Detection rate of 18 F-FDG-PET and PET/CT was reported to increase with serum calcitonin levels C1000 pg/mL [11][12][13]. Despite the sub-optimal sensitivity, 18 F-FDG-PET or PET/CT is performed in patients with biochemical evidence of disease when cross-sectional morphological imaging fails to detect sites of disease or in patients with known metastatic MTC to evaluate disease extension [14].…”

Section: Introductionmentioning

confidence: 99%